The Ewing Sarcoma Treatment Landscape
Driven by curiosity and built on purpose, this is where bold thinking meets thoughtful execution. Let’s create something meaningful together.
How To Use This Information
New possibilities continue to develop, but figuring out what’s right for you or your child is overwhelming. It feels like the world’s worst “choose your own adventure” book—where the stakes couldn’t be higher and the choices are rarely clear.
Think of this page as a starting point—a way to explore what’s out there, ask thoughtful questions, and move forward with as much clarity and confidence as possible.
Use this content in partnership with your medical team.
Things change quickly, let us know if you see something that needs to be updated, changed, or added.
Second Opinions
Remote consults, tumor boards, and more.
New Diagnosis Trials
Frontline options for newly diagnoses patients.
Relapsed & Refractory Trials
Eager to explore life’s big questions?
Searching for a sense of belonging?
Second Opinions
Dr. Pete Anderson | Cleveland Clinic
One of the premier Ewing Sarcoma experts, Dr. Pete conducts hundreds of remote consults per year. He has retired from the clinic, but sill offers virtual guidance. Appointments can be made via his admin, Sammi Garzone: garzones@ccf.org
Dr. Jonathan Gill & Dr. Karen Moody | MD Anderson
This team offers a much sought-after integrative oncology approach—they treat Ewing sarcoma with both cutting-edge medical therapy and comprehensive symptom, emotional, and quality-of-life support. Do we know how this team sets up second opinions? Virtual? In Person only? By referral?
NEWS Tumor Board
The National Ewing Sarcoma Tumor Board (NEWS) pulls multidisciplinary experts from across the country to consult on cases. Leaders in the fields of pediatric & medical oncology, radiation oncology, orthopedic oncology, radiology/IR, pathology and other surgical specialties participate representing leading institutions such as Dana-Farber, Duke, Nationwide Children’s, Seattle Children’s, and Stanford. Recommendations will be delivered back to your oncologist (not to the patient directly).
Your oncologist can submit your case with a question for the board.
Learn More »
Trials & Options for Newly Diagnosed Patients
IN:Formation Next Generation Sequencing Program
Dr. Giselle Sholler | Penn State Health & Beach Childhood Cancer Consortium
The IN:Formation Project uses advanced genomic sequencing to reveal the mechanics, drivers, and targets in your child's unique tumor. Patients may participate in this program when their tumor is biopsied or during surgical local control. Participating helps you and your team learn more about your tumor while also contributing to research. There is an arm of this program that includes treatment recommendations.
This is considered an observational trial. Participation does not include intervention, but it does provide valuable information that may be helpful in relapsed or refractory situations.
Ewing’s U Episode: May 2022 (Dr. Sholler and this program have moved to Penn State Health)
ClinicalTrials.gov: NCT04715178
Location: Multiple Locations, US
Status: Recruiting
METTSEO Trial
Dr. Matteo Trucco & Dr. Jonathan Metts | Cleveland Clinic & H. Lee Moffitt Cancer Center
This Phase 1 trial tests an alternative strategy for widely metastatic Ewing sarcoma by optimizing the sequencing of existing chemotherapy rather than introducing a new drug. METTSEO rotates multi-agent regimens every ~6–8 weeks to limit resistance, applying an evolution-based approach: an initial “first strike” to reduce tumor burden, followed by sequential “second strikes” targeting resistant cells and a maintenance phase to suppress regrowth. The goal is to improve historically poor outcomes by disrupting tumor adaptation.
Ewing's U Episode: April 2025
ClinicalTrials.gov: NCT07194044
Location: Multiple Locations, US
Status: Recruiting
INTER-EWING-1 — Regorafenib + Optimized Standard Therapy
Prof. Bernadette Brennan | University of Manchester / CRUK Clinical Trials Unit
Multi-tyrosine kinase inhibitor + multimodal therapy optimization.
This Phase 2 international trial tests whether adding regorafenib—a multi-tyrosine kinase inhibitor—to standard chemotherapy improves outcomes in newly diagnosed Ewing sarcoma, while simultaneously optimizing radiotherapy dosing and evaluating maintenance chemotherapy. Patients are randomized across multiple arms examining targeted therapy, dose-adjusted radiation, and extended low-dose chemotherapy. The goal is to improve survival by enhancing standard treatment across multiple points of care rather than introducing a single new regimen.
Ewing's U Episode: May 2025
UK Trial Information: Bone Cancer Research Trust
Location: International. UK, Europe, Australia, New Zealand (Not currently offered in the US)
Status: Active
Our Services
Explore our range of services designed to help you move forward with confidence, wherever you're headed next.
SARC037 — Trabectedin + Low-Dose Irinotecan
Dr. Patrick Grohar | CHOP
EWS::FLI1 suppressor + topoisomerase I inhibitor.
This study pairs trabectedin — a drug shown to suppress the EWS::FLI1 fusion protein that drives Ewing sarcoma — with low-dose irinotecan. Trabectedin reverses the EWS::FLI1 transcriptional program, and low-dose irinotecan sustains that effect. Phase 2 results (2024) reported a 33% response rate and ~48% 6-month progression-free survival in relapsed/refractory Ewing sarcoma.
Ewing's U Episode: July 2023
ClinicalTrials.gov: NCT04067115
Location: Multiple Locations, US
Status: Completed
Meet the Team
-
![]()
Monet Goode
FOUNDER
With a vision for building something meaningful, our founder brings a blend of big-picture thinking and hands-on experience.
They set the tone for everything we do. -
![]()
Emmett Marsh
SALES MANAGER
Focused, approachable, and driven by results, our sales manager is all about building strong relationships. They help connect people to the right solutions—with clarity and care. -
![]()
Eleanor Parks
MARKETING DIRECTOR
Creative and strategic in equal measure, our marketing director brings fresh ideas to every campaign. They turn insights into action and help our message resonate with the right audience. -
![]()
Karl Holland
CUSTOMER SERVICE MANAGER
Friendly, attentive, and always ready to help, our customer service manager ensures every interaction is a positive one. They keep communication clear, timely, and human.
